A study published in JNCCN—Journal of the National Comprehensive Cancer Network demonstrated that among all patients with neuroendocrine tumors, the risk of dying of cancer was higher than that of dying of other causes—but mortality varies by primary tumor site.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
